Drug Profile
KHK 2866
Alternative Names: KHK2866Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kyowa Hakko Kirin
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Heparin binding EGF like growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Ovarian cancer; Solid tumours
Most Recent Events
- 17 Apr 2013 Discontinued - Phase-I for Ovarian cancer in USA (IV)
- 05 Mar 2013 Kyowa Hakko Kirin Pharma terminates its phase I trial in Solid tumours including Ovarian cancer in USA (NCT01279291)
- 11 Jan 2011 Phase-I clinical trials in Ovarian cancer in USA (IV)